Lin BioScience, Inc. (TPEX:6696)
Taiwan
· Delayed Price · Currency is TWD 161.00
0.00 (0.00%)
Aug 15, 2025, 2:59 PM CST
Lin BioScience Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Cash & Equivalents | 1,589 | 1,488 | 3,261 | 1,645 | 806.85 | 1,092 | Upgrade
|
| Short-Term Investments | 3,181 | 3,571 | - | - | - | - | Upgrade
|
| Trading Asset Securities | 448.8 | 149.14 | - | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 5,219 | 5,208 | 3,261 | 1,645 | 806.85 | 1,092 | Upgrade
|
| Cash Growth | 25.29% | 59.71% | 98.21% | 103.91% | -26.13% | 832.39% | Upgrade
|
| Other Receivables | 4.96 | 19.37 | 25.47 | 0.11 | 1.49 | 0.03 | Upgrade
|
| Receivables | 4.96 | 19.37 | 25.47 | 0.11 | 1.49 | 0.03 | Upgrade
|
| Prepaid Expenses | 111.72 | 123.27 | 137.69 | - | - | - | Upgrade
|
| Other Current Assets | 1.42 | 0.35 | 0 | 27.01 | 11.21 | 17.11 | Upgrade
|
| Total Current Assets | 5,337 | 5,351 | 3,424 | 1,672 | 819.54 | 1,109 | Upgrade
|
| Property, Plant & Equipment | 40.5 | 50.66 | 58.91 | 65.86 | 5.4 | 7.55 | Upgrade
|
| Other Intangible Assets | 104.58 | 118.4 | 108.91 | 108.92 | 97.12 | 100.23 | Upgrade
|
| Other Long-Term Assets | 4.54 | 6.68 | 4.69 | 4.94 | 1.17 | 1.69 | Upgrade
|
| Total Assets | 5,487 | 5,527 | 3,597 | 1,852 | 923.23 | 1,219 | Upgrade
|
| Accrued Expenses | - | 120.82 | 111.47 | 59.16 | 44.94 | 26.39 | Upgrade
|
| Current Portion of Leases | 14.6 | 16.1 | 13.85 | 10.32 | 2.24 | 2.91 | Upgrade
|
| Other Current Liabilities | 115 | 18.4 | 13.38 | 10.39 | 423.07 | 277.33 | Upgrade
|
| Total Current Liabilities | 129.6 | 155.33 | 138.7 | 79.88 | 470.25 | 306.63 | Upgrade
|
| Long-Term Leases | 10.21 | 17.89 | 29.03 | 36.18 | - | 2.24 | Upgrade
|
| Total Liabilities | 139.81 | 173.22 | 167.73 | 116.06 | 470.25 | 308.87 | Upgrade
|
| Common Stock | 827.25 | 786.3 | 785.16 | 723.19 | 689.9 | 685 | Upgrade
|
| Additional Paid-In Capital | 5,674 | 4,827 | 3,477 | 1,935 | 1,029 | 952.75 | Upgrade
|
| Retained Earnings | -3,533 | -2,907 | -2,162 | -1,475 | -1,162 | -726.93 | Upgrade
|
| Comprehensive Income & Other | -128.68 | 148.35 | 37.34 | 51.55 | -15.93 | 1.52 | Upgrade
|
| Total Common Equity | 2,840 | 2,855 | 2,137 | 1,234 | 541.57 | 912.34 | Upgrade
|
| Minority Interest | 2,507 | 2,499 | 1,292 | 501.86 | -88.59 | -2.35 | Upgrade
|
| Shareholders' Equity | 5,347 | 5,354 | 3,429 | 1,736 | 452.98 | 909.99 | Upgrade
|
| Total Liabilities & Equity | 5,487 | 5,527 | 3,597 | 1,852 | 923.23 | 1,219 | Upgrade
|
| Total Debt | 24.81 | 33.99 | 42.87 | 46.5 | 2.24 | 5.15 | Upgrade
|
| Net Cash (Debt) | 5,194 | 5,174 | 3,218 | 1,599 | 804.61 | 1,087 | Upgrade
|
| Net Cash Growth | 25.82% | 60.78% | 101.30% | 98.70% | -25.99% | 2109.10% | Upgrade
|
| Net Cash Per Share | 64.93 | 65.83 | 43.50 | 22.29 | 11.70 | 17.50 | Upgrade
|
| Filing Date Shares Outstanding | 81.44 | 78.63 | 78.52 | 72.32 | 68.99 | 68.5 | Upgrade
|
| Total Common Shares Outstanding | 81.44 | 78.63 | 78.52 | 72.32 | 68.99 | 68.5 | Upgrade
|
| Working Capital | 5,207 | 5,196 | 3,286 | 1,592 | 349.29 | 802.76 | Upgrade
|
| Book Value Per Share | 34.87 | 36.31 | 27.22 | 17.07 | 7.85 | 13.32 | Upgrade
|
| Tangible Book Value | 2,735 | 2,737 | 2,028 | 1,125 | 444.45 | 812.11 | Upgrade
|
| Tangible Book Value Per Share | 33.58 | 34.80 | 25.84 | 15.56 | 6.44 | 11.86 | Upgrade
|
| Machinery | - | 21.65 | 16.64 | 16.44 | 6.04 | 5.9 | Upgrade
|
| Leasehold Improvements | - | 11.05 | 10.67 | 10.67 | - | - | Upgrade
|
Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.